Docetaxel

Breastfeeding Geriatric Pediatric
  • TRADE NAME: Taxotere (Sanofi-Aventis)
  • INDICATIONS: Metastatic breast cancer, non-small cell lung cancer; with prednisone in hormone refractory prostate cancer; with cisplatin and fluorouracil for gastric adenocarcinoma and squamous cell carcinoma of the head and neck cancer
  • CLASS: Taxane, Antineoplastic
  • HALF-LIFE: 11–18 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Aldesleukin, Aprepitant, Cyclosporine, CYP3A4 inhibitors, Erythromycin, Itraconazole, Ketoconazole, Prednisone, Ritonavir, Sorafenib

PREGNANCY CATEGORY: D

NOTE

Toxic deaths, hepatotoxicity, neutropenia, hypersensitivity reactions, and fluid retention have all been reported.

Contraindicated in patients with hypersensitivity to docetaxel or polysorbate 80, or with neutrophil counts of <1500 cells/mm3.

Our database has 134 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile

or Take a FREE TRIAL

SKIN
HAIR
NAILS
MUCOSAL
CARDIOVASCULAR
CENTRAL NERVOUS SYSTEM
NEUROMUSCULAR/SKELETAL
GASTROINTESTINAL/HEPATIC
RESPIRATORY
ENDOCRINE/METABOLIC
HEMATOLOGIC
OTIC
OCULAR
LOCAL
OTHER
  • Saved Searches
  • Watch Drug

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life Threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric